Eye on Itch: Evommune Initiaties Phase I Study of EVO756 in CSU
Evommune, Inc. is initiating its Phase 1 first-in-human study, evaluating EVO756 in chronic spontaneous urticaria (CSU). By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases, including chronic spontaneous urticaria and inflammatory itch. The Phase 1 study is a […]
Almirall, Etherna Partner to Develop mRNA-based Therapies in Medical Dermatology
Almirall, S.A. (ALM) and etherna are teaming up to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The alliance combines and leverages etherna’s proprietary mRNA capabilities and lipid nanoparticle (LNP) formulations with Almirall’s medical dermatology expertise to accelerate discovery of novel treatment options. Etherna and Almirall will work collaboratively on the research […]
Pediatric nonmelanoma skin cancer
With Jennifer Huang, MD Children without risk factors require vigilance “The general thinking in our specialty is that children who are otherwise healthy don’t get nonmelanoma skin cancers (NMSCs),” said Jennifer Huang, MD. “However, a study my colleagues and I published in the May issue of the Journal of the American Academy of Dermatology suggests […]